MD Anderson and Mirati Therapeutics Announce KRAS Strategic Research and Development Collaboration in Solid Tumors
February 11, 2021
February 11, 2021
HOUSTON, Texas, Feb. 11 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release on Feb. 10, 2021:
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors - adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhi . . .
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati's two investigational small molecule, potent and selective KRAS inhibitors - adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhi . . .